Department of Pharmacy, Mayo clinic, Rochester, MN, USA.
Mayo Clin Proc. 2010 Aug;85(8):711-8. doi: 10.4065/mcp.2010.0006.
To describe the effect of a combination prophylactic regimen of levofloxacin, a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class, with either penicillin or doxycycline on the changing epidemiology of bacterial infections and antimicrobial resistance patterns of isolated organisms in the allogeneic hematopoietic stem cell transplant (HSCT) patient population.
We conducted a single-center, retrospective cohort study of all allogeneic HSCT recipients from January 1, 2003, through August 31, 2008, who received prophylactic levofloxacin in combination with penicillin (or with doxycycline in penicillin-allergic patients) from allogeneic stem cell infusion until neutrophil engraftment.
Of the 258 patients who underwent allogeneic HSCT during the study period, 231 received levofloxacin prophylaxis, 76 (33%) of whom developed an infection within 3 months after transplant. Over time, the ratio of gram-positive to gram-negative (GN) infections decreased from 2.11 in 2004, the first year that GN organisms were isolated, to 1.11 in 2008 (P=.20). Emergence of fluoroquinolone-resistant GN bacteria was observed (P=.02), whereas resistance to extended-spectrum beta-lactams did not change over time. Combined vancomycin-resistant enterococci colonization and infection rates increased during the study period (P=.04). Clostridium difficile colitis was uncommon.
Levofloxacin with penicillin or doxycycline prophylaxis may contribute to the emergence of resistant GN infections in allogeneic HSCT recipients over time. Our findings provide additional support for the current standard of practice of administering empiric monotherapy with an antipseudomonal beta-lactam if these patients develop fever or are suspected to have an infection.
描述左氧氟沙星(一种氟喹诺酮类合成化学治疗抗生素)与青霉素或多西环素联合预防方案对异基因造血干细胞移植(HSCT)患者人群中细菌感染的流行病学变化和分离菌对抗菌药物耐药模式的影响。
我们对 2003 年 1 月 1 日至 2008 年 8 月 31 日期间接受异基因 HSCT 的所有患者进行了单中心回顾性队列研究,这些患者在接受异基因干细胞输注期间接受了左氧氟沙星联合青霉素(青霉素过敏患者联合多西环素)的预防性治疗,直至中性粒细胞植入。
在研究期间接受异基因 HSCT 的 258 例患者中,231 例接受了左氧氟沙星预防治疗,其中 76 例(33%)在移植后 3 个月内发生感染。随着时间的推移,革兰阳性菌与革兰阴性菌(GN)感染的比例从 2004 年(首次分离出 GN 菌的第一年)的 2.11 降至 2008 年的 1.11(P=.20)。观察到氟喹诺酮耐药 GN 菌的出现(P=.02),而对扩展谱β-内酰胺类药物的耐药性并未随时间而改变。在研究期间,万古霉素耐药肠球菌定植和感染的发生率增加(P=.04)。艰难梭菌结肠炎少见。
左氧氟沙星联合青霉素或多西环素预防治疗可能导致异基因 HSCT 受者随着时间的推移出现耐药性 GN 感染。我们的发现为目前的标准治疗实践提供了额外支持,如果这些患者出现发热或疑似感染,可给予经验性单药治疗,如抗假单胞菌β-内酰胺类药物。